Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (Q24202900)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24163057%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

meta-analysis

0 references

title

Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24163057%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

0 references

0 references

1 reference

Plasmodium vivax malaria

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24163057%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2

Prathap Tharyan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24163057%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Gawrie N L Galappaththy

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24163057%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

26 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24163057%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24163057%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24163057%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

CD004389

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24163057%20AND%20SRC:MED&resulttype=core&format=json

Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Compliance with 14-day primaquine therapy for radical cure of vivax malaria--a randomized placebo-controlled trial comparing unsupervised with supervised treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Assessment of the response to reduced treatment schemes for vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Efficacy of different primaquine-based antimalarial regimens against Plasmodium falciparum gametocytemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Primaquine for prevention of malaria in travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

High dose of primaquine in primaquine resistant vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

A 5 days primaquine regimen as anti-relapse therapy for Plasmodium vivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Treatment of vivax malaria on the western border of Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Clinical efficacy of chloroquine followed by primaquine for Plasmodium vivax treatment in Azerbaijan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Can primaquine therapy for vivax malaria be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Primaquine therapy for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Resistance to therapies for infection by Plasmodium vivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Comparative features and outcomes of malaria at a tertiary care hospital in Karachi, Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Prevalence and clinical presentation of glucose-6-phosphate dehydrogenase deficiency in Pakistani Pathan and Afghan refugee communities in Pakistan; implications for the use of primaquine in regional malaria control programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

CONSORT statement: extension to cluster randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Glucose-6-phosphate dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

The hypnozoite and relapse in primate malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Acquired immunity to malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Artemisinin combination therapy for vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

A metropolitan hospital in a non-endemic area provides a sampling pool for epidemiological studies on vivax malaria in Sri Lanka.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

The international limits and population at risk of Plasmodium vivax transmission in 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Geographic structure of Plasmodium vivax: microsatellite analysis of parasite populations from Sri Lanka, Myanmar, and Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

A closer look at multiple-clone Plasmodium vivax infections: detection methods, prevalence and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

The global distribution and population at risk of malaria: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Interventions for helping patients to follow prescriptions for medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Contrasting genetic structure in Plasmodium vivax populations from Asia and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

The first Plasmodium vivax relapses of life are usually genetically homologous

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Primaquine radical cure of Plasmodium vivax: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Extensive microsatellite diversity in the human malaria parasite Plasmodium vivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Clinical features of children hospitalized with malaria--a study from Bikaner, northwest India

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Discovery of the hypnozoite and a new theory of malarial relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

UK malaria treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Insecticide-treated bednets and curtains for preventing malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

The impact of phenotypic and genotypic G6PD deficiency on risk of plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

The 'non-falciparum' malarias: the roles of epidemiology, parasite biology, clinical syndromes, complications and diagnostic rigour in guiding therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Unit-dose packaged drugs for treating malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Vivax malaria: a major cause of morbidity in early infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Plasmodium vivax treatments: what are we looking for?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Therapeutic responses to different antimalarial drugs in vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Thrombocytopenia in vivax and falciparum malaria: an observational study of 131 patients in Karnataka, India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Artemisinin-based combination therapy for the treatment of uncomplicated Plasmodium vivax malaria and the prevention of relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Plasmodium vivax malaria: is it actually benign?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Retrospective analysis of vivax malaria patients presenting to tertiary referral centre of Uttarakhand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Clinical profiles of 13 children with Plasmodium vivax cerebral malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Plasmodium vivax infection during pregnancy: an important problem in need of new solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Mosquito larval source management for controlling malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Primaquine revisited six decades after its discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Therapeutic efficacy of chloroquine in Plasmodium vivax from areas with different epidemiological patterns in India and their Pvdhfr gene mutation pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Histopathology of fatal respiratory distress caused by Plasmodium vivax malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Multilocus genotyping reveals high heterogeneity and strong local population structure of the Plasmodium vivax population in the Peruvian Amazon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Determinants of relapse periodicity in Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Primaquine for preventing relapses in people with Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004389.PUB3

Chloroquine sensitivity of Plasmodium vivax in Thailand

21 January 2018

1 reference

12 December 2020

Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand.

1 reference

12 December 2020

Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections

1 reference

12 December 2020

In-vivo sensitivity of Plasmodium vivax isolates from Rond nia (western Amazon region, Brazil) to regimens including chloroquine and primaquine

1 reference

12 December 2020

Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria.

1 reference

12 December 2020

The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden

1 reference

12 December 2020

The neglected burden of Plasmodium vivax malaria

1 reference

12 December 2020

Plasmodium vivax polymorphism in a clinical drug trial

1 reference

12 December 2020

Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria

1 reference

12 December 2020

Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India

1 reference

12 December 2020

Malaria epidemiology and control in refugee camps and complex emergencies

1 reference

12 December 2020

Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand.

1 reference

12 December 2020

High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations.

1 reference

12 December 2020

Short course schemes for vivax malaria treatment

1 reference

12 December 2020

Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine.

1 reference

12 December 2020

Observations on the treatment of 678 malaria cases with primaquine in an area free from maiaria transmission in Mysore State, India.

1 reference

12 December 2020

Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report

1 reference

12 December 2020

Clinical efficacy of four schemes for vivax malaria treatment in children

1 reference

12 December 2020

Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand

1 reference

12 December 2020

Insecticide-treated nets for preventing malaria in pregnancy

1 reference

12 December 2020

Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.

1 reference

12 December 2020

Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia

1 reference

12 December 2020

Malaria: anti malarial resistance and policy ramifications and challenges

1 reference

12 December 2020

Plasmodium vivax malaria: treatment of primary attacks with primaquine, in three different doses, and a fixed dose of chloroquine, Antioquia, Colombia, 2003-2004

1 reference

12 December 2020

Primaquine for preventing relapses in people with Plasmodium vivax malaria

1 reference

12 December 2020

Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy

1 reference

12 December 2020

Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.

1 reference

12 December 2020

The risk of malarial infections and disease in Papua New Guinean children.

1 reference

12 December 2020

Present status of understanding on the G6PD deficiency and natural selection.

1 reference

12 December 2020

Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development.

1 reference

12 December 2020

Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua

1 reference

12 December 2020

Burden of malaria in India: retrospective and prospective view.

1 reference

12 December 2020

Vivax malaria: neglected and not benign

1 reference

12 December 2020

Relapse/reinfection patterns of Plasmodium vivax infection: a four year study

1 reference

12 December 2020

Interventions for enhancing medication adherence

1 reference

12 December 2020

High-dose primaquine regimens against relapse of Plasmodium vivax malaria

1 reference

12 December 2020

Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria

1 reference

12 December 2020

Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment

1 reference

12 December 2020

Therapeutic efficacy of a regimen of artesunate-mefloquine-primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development

1 reference

12 December 2020

Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border.

1 reference

12 December 2020

Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria

1 reference

12 December 2020

Radical treatment of vivax malaria in Madhya Pradesh, India

1 reference

12 December 2020

A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia

1 reference

12 December 2020

Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens

1 reference

12 December 2020

Efficacy of 5 day radical treatment of primaquine in Plasmodium vivax cases at the BHEL industrial complex, Hardwar (U.P.).

1 reference

12 December 2020

Radical Cure of Chesson Strain Vivax Malaria in Man by 7, Not 14, Days of Treatment with Primaquine *

1 reference

12 December 2020

Efficacy of 5-day radical treatment of P. vivax infection in Tamil Nadu

1 reference

12 December 2020

Comparison of treatment schedules for Plasmodium vivax infections in the Solomon Islands

1 reference

12 December 2020

Field Evaluation of Primaquine in the Control of Plasmodium Vivax *

1 reference

12 December 2020

Radical Cure of Infections with Plasmodium cynomolgi: a Function of Total 8-Aminoquinoline Dose *

1 reference

12 December 2020

Relapses of vivax malaria after a conventional course of primaquine and chloroquine: report of 2 cases

1 reference

12 December 2020

Combined chloroquine-primaquine therapy against vivax malaria

1 reference

12 December 2020

Results of 3-day radical treatment of Plasmodium vivax in North Arcot and South Arcot Districts of Tamil Nadu

1 reference

12 December 2020

Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia.

1 reference

12 December 2020

1 reference

12 December 2020

Primaquine resistance in Plasmodium vivax

1 reference

12 December 2020

Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis

1 reference

12 December 2020

Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels.

1 reference

12 December 2020

Primaquine-tolerant vivax malaria in Thailand

1 reference

12 December 2020

The effect of drug packaging on patients' compliance with treatment for Plasmodium vivax malaria in China

1 reference

12 December 2020

10.1002/14651858.CD004389.PUB3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24163057%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24163057%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference